Core Insights - Ingersoll Rand Inc. has completed the acquisition of Lead Fluid, a company specializing in advanced fluid-handling products for life science applications [1][8] - The acquisition aligns with Ingersoll Rand's strategy to expand its market share and enhance its life sciences business in China [3][8] Acquisition Details - Lead Fluid is headquartered in China and manufactures products such as peristaltic pumps, gear pumps, and syringe pumps, which are crucial for precise fluid delivery [2] - The financial terms of the acquisition have not been disclosed [1] Strategic Rationale - The acquisition is part of Ingersoll Rand's broader growth strategy, which includes acquiring businesses to increase market presence and customer base [3] - Lead Fluid's expertise will be integrated into Ingersoll Rand's Life Sciences platform under the Precision and Science Technologies segment [3][8] Other Acquisitions - Ingersoll Rand has a history of acquisitions, including Air Power Systems, Blutek, and UT Pumps, which have contributed to its growth strategy [4][5] - The recent acquisitions have enhanced the company's capabilities in energy-efficient solutions, high-specification projects, and new pump technology [4][5] Financial Performance - In the first quarter of 2025, acquisitions contributed 8.4% to Ingersoll Rand's total revenues [5] - The company has a market capitalization of approximately $33 billion and currently holds a Zacks Rank of 3 (Hold) [6] Stock Performance - Ingersoll Rand's shares have increased by 7.9% over the past month, outperforming the industry growth of 7.2% [9] - The Zacks Consensus Estimate for the company's earnings in 2025 is $3.32 per share, reflecting a decrease of 2.9% from previous estimates [9]

Core Viewpoint - Ingersoll Rand Inc. has acquired Lead Fluid, a China-based manufacturer of advanced fluid-handling products, to enhance its life science capabilities and support its in-region, for-region growth strategy [1][3]. Group 1: Acquisition Details - Lead Fluid specializes in designing and manufacturing fluid-handling products such as peristaltic pumps, syringe pumps, and gear pumps, with an annual revenue of approximately $8 million [2]. - The acquisition aligns with Ingersoll Rand's strategy of executing bolt-on acquisitions to strengthen its market position in high-growth sectors [3][7]. Group 2: Strategic Implications - The acquisition is expected to enhance Ingersoll Rand's life science capabilities in China, contributing to the overall durability of its portfolio by increasing exposure to sustainable end markets [3]. - The pre-synergy adjusted EBITDA purchase multiple for this acquisition is in the low double-digits, indicating a strategic investment in a growing segment [7]. Group 3: Company Overview - Ingersoll Rand is a global provider of mission-critical flow creation and life science solutions, supported by over 80 respected brands, and is committed to delivering exceptional performance and durability [4].